The 14th biennial meeting saw experts from around the world getting together to present, discuss and debate the latest research and data in malignant lymphoma. The meeting covered a range of subjects related to Hodgkin lymphoma, non-Hodgkin lymphoma, and various lymphoma subtypes. The field is becoming more complex; there are many subtypes of lymphoma and many new agents in development. The outlook for patients is improving and physicians must learn how to use the new agents and techniques to ensure that more patients can benefit from the most up to date guidelines for lymphoma management. Looking beyond the lab and clinic, health economics and the cost of hematological cancer care were also key talking points in Lugano.
This content was supported by Napp Pharmaceuticals Ltd and Janssen Pharmaceuticals (a Johnson & Johnson Company) through an unrestricted educational grant to Magdalen Medical Publishing. These companies had no influence on the production of this content.View all videos
By choosing to continue, you are confirming that you are a healthcare professional